The six-minute walk test in scleroderma: What should we measure and how should we measure it?

Respirology

Volumn 17, Issue 4, 2012, Pages 588-589

  Holland, Anne E ^a,b,c   Goh, Nicole S L ^c,d  

^a LA TROBE UNIVERSITY   (Australia)

^b Alfred Health ^*  (Australia)

^c Institute for Breathing and Sleep   (Australia)

^d AUSTIN HEALTH   (Australia)

Author keywords

exercise test; lung disease, interstitial; monitoring, physiologic; pulmonary fibrosis; scleroderma, systemic

Indexed keywords

OXYHEMOGLOBIN;

CARDIOPULMONARY EXERCISE TEST; DYSPNEA; EDITORIAL; HUMAN; MORTALITY; OUTCOME ASSESSMENT; OXYGEN SATURATION; PRIORITY JOURNAL; PROGNOSIS; PULSE OXIMETRY; SCLERODERMA; SCORING SYSTEM; SIX MINUTE WALK TEST; WALKING;

EXERCISE TEST; FEMALE; HUMANS; LUNG DISEASES; MALE; SCLERODERMA, SYSTEMIC;

EID: 84859917834     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2012.02161.x     Document Type: Editorial

References (20)

1. Tyndall AJ, Bannert B, Vonk M, et al,. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann. Rheum. Dis. 2010; 69: 1809-15.
2. Bryan C, Knight C, Black CM, et al,. Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum. 1999; 42: 2660-5. (Pubitemid 30327188)
3. Fransen J, Popa-Diaconu D, Hesselstrand R, et al,. Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centres. Ann. Rheum. Dis. 2011; 70: 1788-92.
4. Simeon CP, Armadans L, Fonollosa V, et al,. Survival prognostic factors and markers of morbidity in Spanish patients with systemic sclerosis. Ann. Rheum. Dis. 1997; 56: 723-8. (Pubitemid 28064838)
5. Joven BE, Almodovar R, Carmona L, et al,. Survival, causes of death, and risk factors associated with mortality in Spanish systemic sclerosis patients: results from a single university hospital. Semin. Arthritis Rheum. 2010; 39: 285-93.
6. ATS statement: guidelines for the six-minute walk test. Am. J. Respir. Crit. Care Med. 2002; 166: 111-17.
7. Rasekaba T, Lee AL, Naughton MT, et al,. The six-minute walk test: a useful metric for the cardiopulmonary patient. Intern. Med. J. 2009; 39: 495-501.
8. King TE Jr, Behr J, Brown KK, et al,. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2008; 177: 75-81.
9. Raghu G, Brown KK, Costabel U, et al,. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 2008; 178: 948-55.
10. McLaughlin VV, Archer SL, Badesch DB, et al,. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009; 119: 2250-94.
11. Buch MH, Denton CP, Furst DE, et al,. Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test. Ann. Rheum. Dis. 2007; 66: 169-73. (Pubitemid 46226049)
12. Garin MC, Highland KB, Silver RM, et al,. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. J. Rheumatol. 2009; 36: 330-6.
13. Schoindre Y, Meune C, Dinh-Xuan AT, et al,. Lack of specificity of the 6-minute walk test as an outcome measure for patients with systemic sclerosis. J. Rheumatol. 2009; 36: 1481-5.
14. Impens AJ, Wangkaew S, Seibold JR,. The 6-minute walk test in scleroderma-how measuring everything measures nothing. Rheumatology 2008; 47 (Suppl. 5): v68-9.
15. Akdogan A, Kaya EB, Sahin A, et al,. Relationship between left ventricular diastolic dysfunction and six minute walk test in patients with systemic sclerosis. Int. J. Rheum. Dis. 2011; 14: 379-83.
16. Mainguy V, Provencher S, Maltais F, et al,. Assessment of daily life physical activities in pulmonary arterial hypertension. PLoS ONE 2011; 6: e27993.
17. Lama VN, Flaherty KR, Toews GB, et al,. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am. J. Respir. Crit. Care Med. 2003; 168: 1084-90. (Pubitemid 37338937)
18. Flaherty KR, Andrei AC, Murray S, et al,. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am. J. Respir. Crit. Care Med. 2006; 174: 803-9. (Pubitemid 44511662)
19. Swigris JJ, Zhou X, Wamboldt FS, et al,. Exercise peripheral oxygen saturation (SpO2) accurately reflects arterial oxygen saturation (SaO2) and predicts mortality in systemic sclerosis. Thorax 2009; 64: 626-30.
20. Villalba WO, Sampaio-Barros PD, Pereira MC, et al,. Six-minute walk test for the evaluation of pulmonary disease severity in scleroderma patients. Chest 2007; 131: 217-22. (Pubitemid 46122996)